Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intravaginal Prasterone for GSM in Breast Cancer Survivors
NCT06611514Phase 3Not yet recruiting
- Sponsor
- European Institute of Oncology
- Start
- Dec 2024
- Primary completion
- Jan 2027
- Modality
- Allosteric Modulators
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of dehydroepiandrosterone in genitourinary syndrome of menopause (GSM), sponsored by European Institute of Oncology. Primary endpoints: Subjective improvement in genitourinary symptomatology, Evaluation of vulvovaginal and urinary symptoms at 6 months and 3 more. Planned start Dec 2024; status: not yet recruiting.
02
Drugs
dehydroepiandrosterone
03
Conditions
genitourinary syndrome of menopause (GSM)
Beyond the preview
Go deeper on NCT06611514.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06611514.